Gut microbes linked with immunotherapy response in kidney cancer

A recent study published in European Urology had shown that the diversity of microbes in the gut is associated with better outcomes in people with metastatic renal cell carcinoma (RCC) who are taking immunotherapy. There are numerous bacteria and viruses in the gut, called the microbiome. This gut microbiome is increasingly linked to health and […]

read more

ASCO 2020: HIF-2 alpha inhibitor induced positive response for VHL-associated kidney cancer

Results from a phase II international trial led by researchers at MD Anderson Cancer Center in America were presented during the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program. The trial showed treatment with a novel hypoxia inducible factor (HIF)-2 alpha inhibitor (MK-6482) was well tolerated and resulted in clinical responses in patients with von […]

read more

Promising efficacy and safety of seleno-L-methionine plus axitinib in advanced kidney cancer

Data from a recent phase I study of seleno-L-methionine in combination with axitinib (Inlyta) as treatment for patients with previously treated or relapsed clear cell renal cell carcinoma (ccRCC) were presented at the American Urological Association (AUA) Virtual Experience meeting over the weekend. There were 15 patients in the study with ccRCC whose disease had […]

read more

The future of immunotherapy-based combinations for metastatic kidney cancer

The past decade or so has seen the development of multiple targeted therapies for metastatic renal cell carcinoma (RCC), such as vascular endothelial growth factor (VEGF) inhibitors and inhibitors of the mammalian target of rapamycin (mTOR) pathway. Most recently, immune checkpoint inhibitors have been shown to have excellent clinical efficacy. Although patients are living longer, […]

read more

Promising early studies with pegilodecakin plus immunotherapy in pretreated kidney cancer

A recent phase 1b clinical trial investigated the use of pegilodecakin in combination with anti-PD-1 monoclonal antibodies nivolumab or pembrolizumab. The combination showed a “favourable” response in patients with non-small cell lung cancer and kidney cancer. Pegilodecakin works by stimulating the survival, proliferation and “killing” potential of CD8+ T cells, which can recognise and destroy […]

read more

ESMO 2019: Results from JAVELIN-Renal 101 trial for sarcomatoid kidney cancer

Results from the JAVELIN-Renal 101 clinical trial to assess avelumab plus axitinib in untreated patients with advanced renal cell carcinoma (RCC) with sarcomatoid characteristics were presented at the European Society for Medical Oncology (ESMO) conference in Barcelona over the weekend. Sarcomatoid RCC is an uncommon but highly aggressive form of RCC, which tends to have […]

read more

Ilixadencel plus sunitinib combination for metastatic kidney cancer

A combination of ilixadencel plus sunitinib has shown a complete tumour response in patients with metastatic renal cell carcinoma (RCC) in a recent phase 2 clinical trial. Ilixadencel is an off-the-shelf immune primer for the treatment of solid tumours. The clinical trial assessed the effectiveness of combining ilixadencel with sunitinib in 88 untreated patients with […]

read more

Telaglenastat/cabozantinib combination shows early activity in metastatic kidney cancer

Telaglenastat is an oral glutaminase inhibitor and this is the first time it has been administered to humans. Glutaminase is a key enzyme that controls the glutamine pathway that is prominent in renal cell carcinoma (RCC) and important for the tumour to thrive in the body. In pre-clinical models, telaglenastat was found to synergise with […]

read more

Low PD-L1 associated with long term response to sunitinib

Researchers from France have conducted a study to show that metastatic clear cell renal cell carcinoma (RCC) patients who have low expression of PD-L1 also have a long term response to sunitinib. However, low PD-L1 levels suggest a potentially lower impact of immunotherapy in these patients. Read more in Clinical Genitourinary Cancer here

read more

Savolitinib shows promise in first-in-human phase 1 study in solid tumours

Results from a first-in-human phase 1 study of savolitinib in 48 patients with locally advanced or metastatic solid tumours was published in Clinical Cancer Research last month. Savolitinib is a selective MET inhibitor. In the study, the maximum tolerated dose was found to be 800 mg daily, and the recommended dose for phase 2 testing […]

read more
Showing 1 to 10 of 18 results
  TOP